External radiotherapy combined with sorafenib has better efficacy in unresectable hepatocellular carcinoma: a systematic review and meta-analysis
H Li, Z Wu, J Chen, K Su, L Guo, K Xu, T Gu… - Clinical and …, 2023 - Springer
Advanced hepatocellular carcinoma (HCC) has a very low resectable rate. This meta-
analysis aimed to compare efficacy of three combination strategies in treatment of advanced …
analysis aimed to compare efficacy of three combination strategies in treatment of advanced …
[HTML][HTML] Clinical efficacy and safety of external radiotherapy combined with sorafenib in the treatment of hepatocellular carcinoma: a systematic review and meta …
J Chen, K He, Y Han, L Guo, K Su, Z Wu - Annals of hepatology, 2022 - Elsevier
Abstract Introduction and Objectives Both external radiotherapy and sorafenib are promising
treatments for hepatocellular carcinoma (HCC). Nevertheless, the combined treatment of …
treatments for hepatocellular carcinoma (HCC). Nevertheless, the combined treatment of …
Lenvatinib with or without stereotactic body radiotherapy for hepatocellular carcinoma with portal vein tumor thrombosis: a retrospective study
X Ji, Z Xu, J Sun, W Li, X Duan, Q Wang - Radiation Oncology, 2023 - Springer
Background and objectives Patients with hepatocellular carcinoma (HCC) involving portal
vein tumor thrombosis (PVTT) are presently lacking effective treatment options. We aimed to …
vein tumor thrombosis (PVTT) are presently lacking effective treatment options. We aimed to …
Comparison of stereotactic body radiotherapy with and without lenvatinib for advanced hepatocellular carcinoma: a propensity score analysis
Q Wang, X Ji, J Sun, W Li, X Duan, A Zhang - Journal of Cancer Research …, 2023 - Springer
Purpose Lack of evidence on the benefit of stereotactic body radiotherapy (SBRT) in
combination with lenvatinib for advanced hepatocellular carcinoma (HCC). Our research …
combination with lenvatinib for advanced hepatocellular carcinoma (HCC). Our research …
中晚期肝细胞癌的局部治疗联合系统治疗研究进展.
曹白露， 艾敏， 黄平， 杨永峰 - Journal of Clinical Hepatology …, 2023 - search.ebscohost.com
曹白露,艾敏,黄平,杨永峰 Page 1 , DOI:10. 3969 / j. issn. 1001 r 5256. 2023. 08. 031 中晚期肝细胞
癌的局部治疗联合系统治疗研究进展 曹白露,艾敏,黄平,杨永峰 南京中医药大学附属南京医院(南京 …
癌的局部治疗联合系统治疗研究进展 曹白露,艾敏,黄平,杨永峰 南京中医药大学附属南京医院(南京 …
Research advances in local treatment combined with systemic therapy for advanced hepatocellular carcinoma
CAO Bailu, AI Min, P HUANG - 临床肝胆病杂志, 2023 - lcgdbzz.org
Most patients with hepatocellular carcinoma (HCC) have reached the advanced stage at the
time of diagnosis in China, and a single treatment regimen tends to have a low objective …
time of diagnosis in China, and a single treatment regimen tends to have a low objective …
[HTML][HTML] SIB-IMRT combined with apatinib for unresectable hepatocellular carcinoma in patients with poor response to transarterial chemoembolization
X Liu, J Luo, L Zhang, F Yang, D Peng - Clinics and Research in …, 2022 - Elsevier
Abstracts Background Radiotherapy combined with apatinib exhibits synergistic anti-tumor
effect, while the application of simultaneous integrated boost intensity modulated …
effect, while the application of simultaneous integrated boost intensity modulated …
[HTML][HTML] Efficacy and safety for the therapy of liver cancer by combination Sorafenib with other therapies: a literature review
Q Zhang, S Lin - Biotarget, 2022 - biotarget.amegroups.org
Methods: The references in this review are from PubMed, web of science and CBM (China
biomedical literature service system) with the key words of Sorafenib, HCC and so on. Most …
biomedical literature service system) with the key words of Sorafenib, HCC and so on. Most …